Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Prostate cancer is a disease of older adults that has undergone a significant therapeutic
paradigm shift in the last decade with the emergence of novel androgen receptor pathway …

Background Comorbid diseases influence patient outcomes, yet little is known about how
comorbidities interact with treatments for metastatic castrate-resistant prostate cancer …

Background Abiraterone and enzalutamide are second generation androgen receptor
pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without …

This is a retrospective cohort study by analyzing a multi‐institutional electronic medical
records database in Taiwan to compare long‐term effectiveness and risk of major adverse …

Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-
sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies …

Background The potential cardiovascular adverse events associated with new-generation
androgen receptor pathway inhibitors (ARPI) in the treatment of prostate cancer remain …

La terapia de privación androgénica (TPA) es el pilar del tratamiento del cáncer de próstata
hormono-sensible metastásico (CPHSm). La adición de docetaxel o de nuevas terapias …

Background While the cardiovascular risks of androgen receptor pathway inhibitors have
been studied, they were seldom compared directly. This study compares the risks of major …

Background Androgen deprivation therapy (ADT) is the foundational treatment for metastatic
prostate cancer (PCa). Androgen receptor (AR) axis-targeted therapies are a new standard …